Artivion (NYSE:AORT) shares are sliding in the pre-market session today after stopping a trial evaluating Apixaban for patients that have been treated with mechanical aortic valves.
The PROACT Xa trial was designed to study if patients with On-X mechanical aortic valves could be maintained on Apixaban instead of warfarin.
The independent data and safety monitoring board of the trial determined that, “Blood clots, resulting in a stroke, occurred more frequently in patients receiving Apixaban and that continuing the trial was unlikely to achieve the primary endpoint while possibly exposing patients to increased risk.”
Despite the setback, the company has reiterated its guidance of double-digit revenue growth in 2022.
Read full Disclosure